Non-Small Cell Lung Carcinoma – Page 2

FDA Approves BMS’ Opdivo for Perioperative Treatment of Resectable Non-Small Cell Lung Cancer

7 months ago talkbio0Tagged Adjuvant Therapy, Approved, CheckMate-77 T trial, Neoadjuvant Therapy, nivolumab, Non-Small Cell Lung Carcinoma, Opdivo, perioperative, United States Food and Drug Administration

Opdivo (nivolumab), Perioperative treatment, Resectable non-small cell lung cancer (NSCLC), FDA approval, CheckMate-77T trial, Neoadjuvant and adjuvant therapy

FDA Approves Rybrevant for Third NSCLC Indication This Year

7 months ago talkbio0Tagged Approved, Epidermal Growth Factor Receptor, J&J, Malignant neoplasm of lung, Mutation, Non-Small Cell Lung Carcinoma, Rybrevant, United States Food and Drug Administration

Rybrevant, NSCLC, FDA approval, J&J, EGFR mutations, lung cancer treatment

Summit’s Ivonescimab Shows Promising Results Over Keytruda in NSCLC, But Global Validation Needed

7 months ago talkbio0Tagged Antibodies, Bispecific, Ivonescimab, Keytruda, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma

NSCLC, Ivonescimab, Keytruda, Bispecific Antibody, Lung Cancer Treatment

Daiichi Sankyo and Merck Achieve Phase III Success with HER3-Targeted ADC in Lung Cancer

7 months ago talkbio0Tagged Co., Daiichi, Deruxtecan, HER3-Targeted, HERTHENA-Lung02, Non-Small Cell Lung Carcinoma, patritumab, Phase 3 Clinical Trials, Sankyo, therapeutic autologous dendritic cells

Patritumab deruxtecan, HER3-targeted ADC, Non-small cell lung cancer (NSCLC), Phase III trial, HERTHENA-Lung02, Daiichi Sankyo, Merck & Co.

Nuvation Bio Advances with Pooled Data for ROS1-positive Lung Cancer Treatment, Eyes FDA Submission

7 months ago talkbio0Tagged Bio, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Nuvation, ROS1-positive, Submission, taletrectinib, TRUST-I, TRUST-II, United States Food and Drug Administration

Nuvation Bio, ROS1-positive NSCLC, taletrectinib, TRUST-I, TRUST-II, FDA submission, lung cancer treatment

Innovent Biologics Reports Promising Results in Early-Stage Study of Bispecific Antibody IBI363 in Lung Cancer Patients

7 months ago talkbio0Tagged Antibodies, Bispecific, Biological Factors, Early-Stage Study, IBI363, Innovent, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, PD-1/IL-2, α-bias

Innovent Biologics, IBI363, Bispecific Antibody, Lung Cancer, Early-Stage Study, PD-1/IL-2 α-bias, Non-Small Cell Lung Cancer (NSCLC)

AstraZeneca and Daiichi Sankyo’s Dato-DXd Fails to Meet Overall Survival Goal in NSCLC Study, FDA Decision Looms

8 months ago talkbio0Tagged AstraZeneca, Clinical Research, Daiichi, Dato-DXd, Datopotamab deruxtecan, Decision, Non-Small Cell Lung Carcinoma, Overall Survival, Sankyo, TROPION-Lung01, United States Food and Drug Administration

AstraZeneca, Daiichi Sankyo, Dato-DXd (datopotamab deruxtecan), Non-small cell lung cancer (NSCLC), Overall survival (OS), FDA decision, TROPION-Lung01 study